Symposium
Thu. May 20, 2021 4:15 PM - 6:15 PM Room 07 (ICC Kyoto 1F Room D)
Chair：Murai Hiroyuki(International University of Health and Welfare),Suzuki Shigeaki(Department of Neurology, Keio University School of Medicine)
Treatment for myasthenia gravis (MG) is drastically changing. High dose and long-term steroid administration is no longer recommended. Instead, early fast-acting treatment using immunoglobulin and/or plasmapheresis has been utilized widely. Recently, molecular targeted drugs have emerged and changing the scene of the MG treatment. In this symposium, we would like to discuss over these new medicines such as complement inhibitors, FcRn inhibitors and B-cell antibodies. Debate on economic issue will also be planned since these drugs are very expensive and could be a big burden to the society.
○Angela Genge1,2 (1.McGill University, Canada, 2.Montreal Neurological Institute and Hospital, Canada)
Schedule
Like
)
○Akiyuki Uzawa (Graduate School of Medicine, Chiba University, Japan)
Schedule
Like
)
○Shingo Konno (Department of Neurology, Toho University Faculty of Medicine, Japan)
Schedule
Like
)
○Jason L. Crowell1,2 (1.Neurologist, Beth Israel Deaconess Medical Center, 2.Jerome H. Grossman M.D. Graduate Fellow, Harvard Kennedy School)
Schedule
Like
)